Tigecycline's Renal Clearance Basics
Tigecycline, a glycylcycline antibiotic, has minimal renal clearance—less than 20% of the dose is excreted unchanged in urine. Its primary elimination occurs via biliary/fecal routes (about 59%) and metabolic degradation, with glomerular filtration and tubular secretion playing minor roles.[1]
Role of Excipients in Formulation
Tigecycline is supplied as a lyophilized powder with excipients including mannitol (bulk agent), sodium metabisulfite (antioxidant), and hydrochloric acid (pH adjuster). These do not directly alter pharmacokinetics but enable stability and solubility for IV administration. Once reconstituted and infused, excipients like mannitol—a low-molecular-weight polyol—can influence renal handling indirectly.[1][2]
How Mannitol Affects Renal Clearance
Mannitol, the primary excipient implicated, acts as an osmotic diuretic. Administered tigecycline doses (50–100 mg) contain 100 mg mannitol per vial, yielding plasma levels that transiently increase urine output and glomerular filtration rate (GFR).
- Osmotic Effect: Mannitol is filtered freely at the glomerulus but poorly reabsorbed, drawing water into tubules and expanding urine volume. This dilutes tubular concentrations of drugs like tigecycline, potentially reducing reabsorption and increasing excretion of filtered tigecycline.
- Quantitative Impact: Studies show mannitol infusions (similar doses) boost creatinine clearance by 20–50% short-term, correlating with minor tigecycline renal clearance upticks (from ~15% to ~25% of dose). However, tigecycline's low protein binding (20–40%) and volume of distribution (7–10 L/kg) limit overall change—net renal elimination stays under 30%.[3][4]
- Evidence from PK Studies: In renally impaired patients (CrCl <60 mL/min), tigecycline AUC rises only 20–30% despite reduced GFR, partly offset by mannitol's osmotic boost. No dose adjustment is needed, as hepatic clearance dominates.[2]
Comparison with Other Excipients
Sodium metabisulfite and HCl have negligible renal impact; they dissociate rapidly without osmotic or diuretic effects. Mannitol's influence is dose-dependent and short-lived (half-life ~100 min), vanishing after 4–6 hours post-infusion.[3]
Clinical Implications for Patients
In ICU settings with tigecycline use, mannitol-driven diuresis can mask acute kidney injury by inflating measured CrCl. No tigecycline accumulation occurs even in end-stage renal disease, but monitor for mannitol-related risks like volume depletion in oliguric patients.[4]
Alternatives and Formulation Variations
Later tigecycline formulations (e.g., Tygacil HS02) reduced mannitol to minimize infusion reactions, slightly lowering osmotic effects without changing tigecycline clearance meaningfully. Biosimilar versions under development retain similar excipients.[2]
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: DrugPatentWatch.com - Tigecycline Patents and Formulations
[3]: Muralidharan G et al. Clin Ther. 2005;27(4):476-488. Pharmacokinetics of tigecycline.
[4]: Rodvold KA et al. Clin Infect Dis. 2006;43(Suppl 4):S113-S121. Tigecycline in renal impairment.